期刊
BIOMICROFLUIDICS
卷 16, 期 5, 页码 -出版社
AIP Publishing
DOI: 10.1063/5.0109017
关键词
-
资金
- U.S. Food and Drug Administration (FDA)
- [75F40119C10122]
This study introduces a method called acoustophoresis for the separation of T cells from blood products, achieving high purity without the use of magnetic beads. By conjugating affinity reagents with red blood cells and undesired white blood cells, a cell-cell complex with increased acoustic mobility is formed, resulting in up to 99% purity of T cells.
Breakthrough cell therapies for the treatment of cancers require the separation of specific cells, such as T cells, from the patient's blood. Current cell therapy processes rely on magnetic separation, which adds clinical risk and requires elevated manufacturing controls due to the added foreign material that constitutes the magnetic beads. Acoustophoresis, a method that uses ultrasound for cell separation, has demonstrated label-free enrichment of T cells from blood, but residual other lymphocytes limit the ultimate purity of the output T cell product. Here, to increase the specificity of acoustophoresis, we use affinity reagents to conjugate red blood cells with undesired white blood cells, resulting in a cell-cell complex (rosette) of increased acoustic mobility. We achieve up to 99% purity of T cells from blood products, comparable to current standards of magnetic separation, yet without the addition of separation particles. Published under an exclusive license by AIP Publishing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据